TERMIS BPC #TERMIS2022

The only Global start-up accelerator programme specific to tissue engineering and regenerative medicine fields. Click to subscribe:

[TERMIS SYIS EU @SyisEu]

Are you attending @TermisEU2022? 🎊
Here is a list for you to check:
1. Tickets ready?✈️
2. Accomodation booked? 🏨

So you just need to vote for 2 panels happening with @SyisEu from the poll below👇

[TERMIS-EU 2022 Krakow @TermisEU2022]

Well well ... basically 2⃣ months to go! #TERMISEU2022
🇵🇱 A stunning city 🏰🐉 and an amazing scientific community👩‍🔬 are waiting for you!

[TERMIS-EU 2022 Krakow @TermisEU2022]

Good news!
💊 D e a d l i n e E x t e n d e d 🧫
to December 15th, 2021📆
Submit your Symposium Proposal, we look forward to receiving amazing proposals and get inspired by innovative thinking! #term #tissueengineering #regenerativemedicine

[TERMIS SYIS EU @SyisEu]

Starting in 10 minutes!

[TERMIS BPC #TERMIS2022 @TERMISBPC]

@antodg16 we would love to hear where you are now!

[TERMIS BPC #TERMIS2022 @TERMISBPC]

Need some advice writing your startup's business plan? We have a series of 5 pre-recorded webinars available on-demand to help you get your TERM assets through to market. Get first-hand advice from a series of industry leaders at the link. https://t.co/fCmEUJBnGt

[TERMIS BPC #TERMIS2022 @TERMISBPC]

Only just over a month left to apply for the 2019 TERMIS-EU BPC! Get your business plans ready and submit now for a chance to present your startup at the @EuTermis 2019 European Congress. Apply here -> https://t.co/ftzVUeR0ID

[TERMIS BPC #TERMIS2022 @TERMISBPC]

The 2019 TERMIS Business Plan Competition @TERMISBPC is open for applications!! If your tissue engineering/regen med startup needs mentorship & a cash boost, visit https://t.co/P9MgUJJQAu and hit 'Apply' for a chance to pitch at TERMIS-EU 2019.

[TERMIS BPC #TERMIS2022 @TERMISBPC]

Take your startup success to the next step after @TERMISBPC - applications for @RebelBio Accelerator are open until 1st July - an opportunity win £200K on a three month incubator programme. #startup #lifescience

[TERMIS BPC #TERMIS2022 @TERMISBPC]

https://t.co/dTjah23lCL https://t.co/grrvqJVjNQ

[Sven Kili @Biosurgerysven]

Avro bio files for $86m IPO and set to become a major player in the ultra rare gene therapy space. https://t.co/RLSP2Chzi2

[Shiraz Ziya 🔬🎬👨🏾‍🔬🏃🏻‍♂️ @shirazziya]

All star meeting @Stanford with a community of #celltherapy centres represented ft. David DiGiusto, Adrian Gee, Bruce Levine @StanfordMed @CAGTHouston @BLLPHD @PennMedicine @Baylor @ISCTglobal @TERMISBPC

[FierceBiotech @FierceBiotech]

Autolus, Arix and Syncona all emphasized that the IPO plan is in the preliminary stages and that the timing and terms are yet to be nailed down. The IPO could even fall through altogether: https://t.co/QvabxMIZ2x

[TERMIS BPC #TERMIS2022 @TERMISBPC]

https://t.co/lWs75W6dFW https://t.co/xJ62OVhUIz

[Cell and Gene Therapy Catapult @CGTCatapult]

A memorandum of understanding between @CGTCatapult and the Japanese Society for Regenerative Medicine was signed today. Pictured are Dr John Brown, CGTCatapult Chairman, and Yoshiki Sawa, President @JSRM_Official #Collaboration #RegenerativeMedicine - https://t.co/SHrcQHRIR6

[Innovate UK @innovateuk]

#Autolus develops cancer therapies which will hopefully #transform lives with new therapies such as T-cell therapies #Innovateblog @innovateuk @UKRI_News https://t.co/DoDdK1jkgZ

[TERMIS BPC #TERMIS2022 @TERMISBPC]

Secondments can provide invaluable opportunity to broaden your skills, think laterally and change your perspective. @MeDe_Innovation @ISCTglobal @SyisEu #phdchat #ecrchat https://t.co/U5TiwB58cu

[Danielle Miles @Dr_D_Miles]

The value of a secondment to a Medtech Researcher https://t.co/FPa3FhDoLR #secondment #researcher #leedscityregion @TranslateMedTec

[Cell and Gene Therapy Catapult @CGTCatapult]

Case study: How @CGTCatapult worked with #cryochain technology experts @Asymptote_Ltd to create a new product and solve barriers in thawing #supplychain #coldchain - https://t.co/xXR8IuSx9f

[MIT Technology Review @techreview]

The cost of gene therapy is trending steadily downward, which is theoretically great for patients, but it still remains to be seen whether insurance will cover them. https://t.co/44zcg6DgpT

[Simon ellison @Simon_H_Ellison]

Fujifilm and Takeda Announce Collaboration to Develop Regenerative Medicine Therapies using Cardiomyocytes Derived from iPSC https://t.co/wje5RB7aIq